ALDX Aldeyra Therapeutics, Inc.
USHealthcareAs of 2026-07-08 16:00
Why ALDX matters now
Aldeyra Therapeutics, Inc. (ALDX) is a US stock in Healthcare. The latest InvestLog snapshot shows $2.13 with -4.48% on the session and $128.5M in market capitalization; recent performance reads 1-month +27.27% and YTD -62.16%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-3.5M, and EPS of $-0.06. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -22.0%.
The latest indexable market news headline is "Levicept Appoints Darlene Deptula-Hicks as CFO" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $10.00; recent insider activity includes DEPTULA-HICKS DARLENE M filing . These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
2.80
P/S
0.00
EV/EBITDA
-2.73
DCF Value
$0.91
FCF Yield
-22.0%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-57.3%
ROA
-41.2%
ROIC
-49.2%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-3.5M | $-0.06 |
| Q4 2025 | $0.00 | $-6.5M | $-0.11 |
| FY 2025 | $0.00 | $-33.8M | $-0.56 |
| Q3 2025 | $0.00 | $-7.7M | $-0.13 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$9.67
Target (Median)
$10.00
Target Range
$7.00 - $12.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
1.19
Aldeyra Therapeutics, Inc. is a biotechnology company focused on the discovery and commercialization of therapeutic agents for ocular and systemic immune-mediated disorders. The firm's primary investigational compound is reproxalap, a reactive aldehyde species (RASP) modulator, currently in Phase III clinical trials for addressing dry eye disease and allergic conjunctivitis. Additionally, Aldeyra is advancing ADX-629, an innovative, first-in-class RASP modulator designed for oral administration, which is undergoing Phase II studies for conditions such as psoriasis, asthma, and COVID-19. Another pipeline asset, ADX-2191, a dihydrofolate reductase inhibitor, is in Phase 3 for the prevention of proliferative vitreoretinopathy and in Phase II trials for treating retinitis pigmentosa and primary vitreoretinal lymphoma. The company also holds a license agreement with Madrigal Pharmaceuticals, Inc. for the development of ADX-1612, a compound that inhibits the protein chaperome to tackle inflammatory diseases. Originally incorporated in 2004 as Aldexa Therapeutics, Inc., the company officially adopted the name Aldeyra Therapeutics, Inc. in March 2014 and is headquartered in Lexington, Massachusetts.